Emerging Artificial Intelligence Imaging Applications for Stroke Interventions

Stroke is the most frequent cause of acquired disability and the fifth most frequent cause of death in the United States. Treatment options for acute ischemic stroke (AIS) caused by largevessel occlusion (LVO) are rapid recanalization of the occluded large vessels using IV thrombolysis with alteplase (recombinant tissue plasminogen activator) within 4.5 hours and mechanical thrombectomy (MT) within 6 hours. In either treatment, identifying a substantial and salvageable ischemic penumbra is essential for a patient to be eligible for therapy. Recent randomized controlled trials—Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention with Trevo (DAWN), Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE-3), and Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (WAKE-UP)—that revolutionized the management of patients with LVO stroke laid the foundation for a further revolution in the selection of patients eligible for late MT, up to 24 hours, regardless of whether they receive IV alteplase for the same ischemic stroke event. An ongoing phase III trial (Tenecteplase in Stroke Patients Between 4.5 and 24 Hours; TIMELESS) is investigating the efficacy of tenecteplase in an extended time window from 4.5 to 24 hours. Because of rapid changes in the evidence, the American Heart Association/American Stroke Association updated their acute stroke guidelines from 2018, which replaced the 2013 guidelines. In this context, a transition takes place from the concept of a “temporal therapeutic window” to that of a “cerebral tissue window” accounting for the degree of collateral perfusion, incorporating advanced neuroimaging methods, such as CT perfusion and MR imaging with FLAIR, diffusion, and perfusion-weighted imaging, for the assessment ischemic core (irreversibly damaged tissue) and of ischemic penumbra (potentially reversible ischemic tissue). The best method for the correct selection of such patients is still a matter of debate. Nevertheless, because the benefit of reperfusion therapy decreases over time, it is critical to treat patients as quickly as possible before cell death ensues. However, several challenges may limit the widespread clinical use of LVO stroke interventions, specifically MT. Indeed, only 13,000 MTs were performed in the United States as of 2016 (,2% of total AIS cases). First, only an estimated 10% of patients with AIS have a proximal LVO in the anterior circulation and present early enough to qualify for MT within 6hours, but approximately 9% of patients presenting in the 6to 24-hour time window may qualify for MT. Second, after the patient arrives at a medical center, urgent imaging, either CT or MR imaging, is performed and must be promptly analyzed by qualified radiologists to determine if MT is required. However, image interpretation is subject to inconsistent local expertise and time delays and varies between institutions. Third, because of increasing centralization of acute stroke care at specialist facilities, only a few stroke centers have sufficient advanced neuroimaging and neurointerventional resources and expertise to deliver this therapy, which make it necessary to transfer eligible patients from a primary stroke center to a comprehensive stroke center, many times after initiation of thrombolysis, a strategy called “drip and ship. ” Even at experienced facilities, activation of interhospital communication for LVO triage and transport to a thrombectomy center can be operationally challenging. To address this need, artificial intelligence (AI) tools using machine learning algorithms are being developed as a rapid clinical decision support system for complete assessment and identification of LVO. These tools can automatically generate quantitative measures, such as a patient’s Alberta Stroke Program Early CT Score calculated on noncontrast CT, process perfusion maps and determine salvageable brain tissue on CT or MR perfusion imaging, and detect LVO on CT angiography. Thereafter, the resultant data are automatically delivered with email or text notifications on a cellphone application to the relevant emergency department and stroke team members, aiming to achieve faster onset-to-treatment time in fibrinolytic-eligible patients and MT-eligible patients. Additional outputs can be sent as DICOM images or to a web browser user interface. Over the past several years, a few software platforms have been commercialized, of which some of the most popular are RapidAI (iSchemaView), e-Stroke-Suite (Brainomix Ltd) in collaboration with Olea Sphere (Olea Medical Solutions), and VIZ. ai (Viz.ai). Other similar solutions from different companies are being developed with different stages of pending European CE mark or FDA approval. The applications share the same concept but have variations regarding the algorithm and available features.